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Increase in non-specific bronchial 
hyperresponsiveness without specific response to 
isocyanate in isocyanate-induced asthma: a pilot 
study 
M. C. KOPFERSCHMITT-KUBLER”+, N. FROSSARD*, G. ROHDE+ AND G. PAULI”’ 
“INSERM U 425, Neuvoimmunopharmacologie Pulmonaire, ‘Service de pneumologie, 
Hspitaux Univeusitaives, BP 426, 67091 Stvasbouvg Cedex, France 
Increased non-specific bronchial hyperresponsiveness (BHR) has been reported after positive reaction to isocyanates 
in patients with isocyanate-sensitive asthma. The increased responsiveness may, however, also precede the asthma 
attack. We therefore compared non-specific BHR to a cholinergic agent before and after exposure to toluene- 
diisocyanate (TDI) that induced no asthma symptoms in 11 workers with isocyanate-related asthma. Patients were 
exposed for 3 consecutive days to progressively increasing doses of TDI (5; 10, and 20 ppb min - ’ for 20 min) in an 
exposure chamber with continuous TDI monitoring. No immediate nor late asthmatic bronchial reaction was 
observed in any patient after any dose of TDI during or after challenge. A significant increase in non-specific BHR 
was noted 24 h after the last dose of TDI challenge, however. This increase was at least one doubling dose for seven 
of 11 patients. 
In conclusion, our study shows that, in patients with isocyanate-induced asthma, exposure to TDI induces a slight 
but significant increase in non-specific BHR in the absence of any immediate or late bronchial response to 
isocyanate. This result, which requires further confirmation, may justify a proposal to measure non-specific BHR: 
even after a negative specific inhalation test to TDI: as an additional diagnostic element for TDI-induced 
occupational asthma, to help lower the percentage of the undetected occupational asthma cases. 
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Introduction 
Increased bronchial hyperresponsiveness (BHR) after a 
positive allergen challenge test has been widely documented 
(l-3). Similarly, BHR increases after a positive bronchial 
provocation test to toluene diisocyanate (TDI), both after 
late or dual reactions (4) and after an immediate response 
(5). In allergic asthma, repeated inhalation of low doses of 
allergens that do not provoke by themselves any broncho- 
constrictive response may induce an increase in non-specific 
BHR (6). Hence, we hypothesized that non-specific BHR 
might also increase after a negative occupational allergen 
challenge and might be useful in diagnosing occupational 
asthma. This aspect of BHR has hitherto received little 
attention (7,8). 
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We report here the changes in non-specific BHR in 11 
patients with isocyanate-induced asthma who were exposed 
to increasing low doses of isocyanate that did not induce a 
positive bronchial reaction. 
Patients and Methods 
PATIENTS 
This study included 11 patients: 10 men and one woman, 
aged 2746 years (mean: 36.1 GC 7.3 years) (Table I). All had 
a clinical history of isocyanate-induced asthma, character- 
ized by chest tightness, dyspnoea, and wheezing on work 
days which was reversible with &agonists. Symptoms 
improved or disappeared on days off (9). All patients were 
hospitalized for the study. These patients were chosen 
because they had no positive reaction to low doses of TDI 
administered on 3 consecutive days (5: 10, 20 ppb). 
Five patients (nos 1, 2, 4, 6, 11) had completed a 1 -month 
diary card that listed their workdays, tasks, and symptoms 
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TABLE 1. Characteristics of the patients before and after 
TDI challenge 
Patient Age 
Before TDI After TDI AFEViB 
FEVIB (1) FEVIB (1) (“A) 
2 
4 
5 
6 
I 
8 
9 
10 
11 
28 
41 
31 
27 
29 
43 
39 
41 
45 
27 
3.5 3.5 0 
3.3 3.2 3.0 
2.4 2.5 4.2 
3.0 2.9 3.3 
4.3 4.3 0 
3.9 4.0 3.8 
2.8 2.7 2.9 
3.6 3.6 1.4 
3.8 3.6 4.0 
3.6 3.5 2.8 
3.3 3.2 2.4 
Mean 36.1 3.4 3.4 2.5 
SD 7.3 0.5 0.5 1.4 
46 
FEViB, baseline FEV, before cholinergic challenge. 
for the month. Peak flow was evaluated at least three 
times daily during that month. Changes between the 
maximum value obtained on days off and the minimal PEF 
value observed at the workplace were calculated as the 
percentage: (max-min)/max x 100. Peak flow values of all 
five patients dropped significantly (>20%) on work days. 
Two of 11 patients had specific IgE to TDI. Six of 11 
patients had positive skin prick tests to indoor allergens, 
pollens, or both, and only one had asthma before exposure 
to TDI (horse and dog contact). Two patients were smokers 
and six were ex-smokers. 
Patients were not exposed to isocyanates at work for at 
least 2 days before inclusion and were hospitalized during 
the study for extensive investigation. All medications were 
stopped before the study: 15 days before for inhaled 
corticosteroids and 12 h before for immediate /&-agonists. 
STUDY DESIGN 
Patients underwent a cholinergic provocation test to evalu- 
ate bronchial responsiveness l-4 days before the initial TDI 
challenge. They were then challenged on 3 consecutive days 
with TDI at increasing doses (5, 10, and 20 ppb for 20 min 
on days 1, 2, and 3, respectively). A second cholinergic 
provocation test was performed 24 h after the highest TDI 
dose (20 ppb), and the two dose-response curves were 
compared. 
METHODS 
Provocation tests to the cholinevgic agent 
The non-specific bronchoprovocation test was carried 
out by administering increasing doubling doses of the 
cholinergic agent. Methacholine aerosol (solution 11100 in 
saline) was generated from a starting volume of 2ml in 
a disposable Minineb 5610 5610 DeVilbiss nebulizer 
(Somerset, PA, U.S.A.) by means of a breath-activated 
dosimeter (FDC 88; Mediprom, Paris, France) under a 
pressure of 1.5 bar. During inhalation through a 
mouthpiece, the subject wore a noseclip. Each dose of 
aerosol was delivered during a breath taken slowly with a 
2-5 s breath-hold from residual capacity to near total lung 
capacity. The nebulizer delivered 4, 8 or 16,ul per breath 
depending on the nebulization time (0.6, 1.2 or 2.4 s), 
leading to inhalation of cumulative doubling doses of 
25-32OOpg methacholine. Doses were expressed in base 2 
logarithm, i.e. log, doses from 1 to 8. 
Airway responses were assessed by the measurement of 
the FEV, with an automated flowmeter (Autospiro AS500, 
Minato, Osaka, Japan). Challenges were preceded by the 
inhalation of 0.9% NaCl, which caused no or less than 5% 
change in FEV, in any of the subjects. A positive test was 
stopped when a fall in 20% in baseline FEV, occurred. Two 
puffs of &agonist were administered and the reversibility 
of the bronchospasm was evaluated by measuring FEV, 
10 min later. 
When a fall of less than 20% was observed for the highest 
dose of the cholinergic agent, the test was considered 
negative. 
TDI provocation test 
The inhalation of TDI took place in a dynamic flow 
chamber where the airborne concentration of isocyanate 
was continuously measured with an MDA monitor (7100 
MDA Scientific, Grenview, IL, U.S.A.). Exposure lasted 
for 20 min. 
TDI was generated by heating 10 ml of TDI in a closed 
cell, with a controlled flow rate into a mixing chamber. 
There, a fan ensured adequate mixing and circulation of air 
with the TDI vapour. FEV, was measured before exposure, 
immediately after, and hourly for 8 h. If symptoms 
occurred later, FEV, was measured again. For this reason, 
the patients stayed in the hospital for 3 days. 
EXPRESSION OF THE RESULTS AND 
STATISTICAL ANALYSIS 
Individual dose-response curves were constructed and 
PD20, i.e. the dose inducing at least a 20% fall in FEV,, was 
calculated for each subject. Doubling doses were used for 
both tests, in accordance with previous studies of between- 
test reproducibility of cholinergic challenge tests with the 
dosimeter method (10). 
Two-way analysis of variance (ANOVA) was used 
to analyse the curves (Statview II, Abacus concept, 
U.S.A.). 
To test for changes in cholinergic airway responsiveness, 
the logarithm base 2 values for cholinergic doses (PD20) 
before and after TDI inhalation were compared by a 
Wilcoxon rank test. When the cholinergic test before TDI 
challenge was negative at the highest dose used (32OOpg 
MCh), the positive dose was considered as the dose 
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immediately above, which corresponds to the less favour- 
able hypothesis. A P value lower than 0.05 was considered 
significant. 
Results 
TDI INHALATION 
All 11 subjects tolerated the inhalation of TDI up to 
20 ppb without either an immediate or a late asthmatic 
reaction. 
CHALLENGE TEST TO THE CHOLINERGIC 
AGENT 
The baseline FEV, of each subject was identical on both 
study days (Table 1, Fig. 1). 
Specific BHR to the cholinergic agent before the TDI test 
was negative in three patients (nos 1: 6; 10). One of them 
(no. 1) showed non-specific BHR 24 h after the last TDI 
challenge, with a variation of one doubling dose before and 
after TDI (Table 2, Fig. 1). Of the eight subjects with 
positive cholinergic provocation tests before TDI challenge, 
airway responsiveness increased in six (nos 2, 3, 5, 8, 9% 11) 
24 h after the last dose of TDI. Two patients exhibited a 
change of three doubling doses before and after TDI (no. 3, 
9); and four patients had a change of one doubling dose 
(Table 2). In the two remaining patients (nos 4; 7), airway 
responsiveness to the cholinergic agent did not vary. 
For the group as a whole, the dose-response curves to the 
cholinergic agent before and after TDI administration of 
TDI differed significantly (P<O.Ol) (Fig. 1). PD20, i.e. the 
provocation doses inducing at least a 20% fall in FEV,, 
decreased significantly (P<O,Ol) by a doubling dose in four 
patients and by more than a doubling dose in three others 
(Fig. 1). 
In the nine patients with positive cholinergic provocation 
after TDI challenge, mean FEV, fall at PD20 was 23.5% 
after challenge; before the challenge it was 11’8% at the 
same dose of methacholine (P<O.O2) (Table 2). 
Discussion 
Our results show that a TDI provocation challenge that 
induced no fall in FEV, in isocyanate-sensitive patients led 
to a slight but significant increase in non-specific BHR. This 
increase may be related to the observed increase in non- 
specific BHR after exposure of workers to their work 
environment (11-14). 
One strength of our study is that optimal study con- 
ditions. The patients were hospitalized, i.e. away from work 
and isocyanates. They were also clinically stable. Mean 
baseline FEV, varied by less than 3%. These excellent 
conditions resulted in a 95% confidence interval for PD20 
of less than the difference of one doubling dose (15). 
Increases occurred after patients were exposed to permis- 
sible exposure levels of isocyanates, between 5 ppb and the 
threshold value of 20 ppb. In our group of 11 patients, three 
had negative cholinergic provocation tests before exposure 
to the specific inhalation challenge test. This result con- 
forms with observations in larger series of TDI-asthmatic 
patients, which report that between 10% and 21% of 
patients had negative methacholine tests (16-18). 
Several studies report that a positive TDI challenge test 
in TDI-sensitive asthma is followed by an increase in BHR 
to a cholinergic agent. This result has been observed most 
often after a late reaction to TDI (4,12), but also after 
immediate isolated reactions (5). The temporal relationship 
between increased non-specific BHR and late asthmatic 
responses induced by several occupational agents, including 
TDI, was studied by Durham et al. (13), who found that the 
increase in histamine responsiveness takes place approxi- 
mately 3 h after exposure to TDI, thus preceding the late 
asthmatic response. BHR remained elevated 24 h after TDI 
challenge, although its intensity was lower. In our study, 
even in the absence of a positive TDI challenge test, a 
significant, although slight: increase in BHR occurred 24 h 
after challenge. Since the patients were followed clinically 
for 24 h with repeated functional respiration tests after the 
last TDI inhalation, any positive early or late specific 
response would have been detected. It is therefore very 
unlikely that the observed increase in BHR was related to a 
late response. Hence, an increase in BHR may precede a 
positive TDI response. Several other results support this 
conclusion. These include a case study reporting an increase 
in non-specific BHR without any positive response to red 
cedar allergen (15), and the study by Ihre et al. (6), in which 
repeated inhalations of low doses of aeroallergens increased 
non-specific BHR in 11 of 13 patients with seasonal allergic 
asthma. Finally, this conclusion is consistent with exper- 
imental studies of occupational disease performed in ani- 
mals: non-specific BHR increases after exposure to low 
doses of TDI in the absence of a specific response (19). 
Our results might be important in lowering the 
percentage of undetected occupational asthma cases, which 
is suspected to be high. Various studies report that, of 
patients who have respiratory symptoms and are exposed to 
isocyanate in the workplace, only half have positive iso- 
cyanate tests (l&20). Proposed explanations have included 
the timing of the challenge test (at a moment when the 
patients had been unexposed for a long period) and a lower 
duration and doses of laboratory exposure, which: because 
limited to the 20 ppb threshold dose of TDI for 10 min, 
were lower than those inducing asthma symptoms in the 
workplace. One conclusion to be drawn from our finding 
that BHR increased although there was no positive TDI 
reaction is that the patients were sensitive to TDI. Measur- 
ing BHR after provocation with low doses of TDI might 
therefore decrease the number of cases of TDI-induced 
asthma that go undetected. Support for this comes from a 
recent report that patients with a modified BHR 6 h after a 
first negative challenge test to an occupational agent 
reacted positively to this agent after a second exposure of 
2-3 h (8). This conclusion is also in accordance with our 
previous finding of a positive TDI-challenge test to 20 ppb 
occurring after an increase in BHR observed after a 5 
and 10 ppb inhalation challenge without positive response 
(7). Thus, these reports suggest that the performance of 
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FIG. 1. Individual dose-response curves to the cholinergic agent (methacholine) (ChA, increasing doubling doses) in 
patients with a clinical history of TDI asthma before (0) and after (0) inhalation of low doses of TDI (5, 10 and 20 ppb) 
on 3 conse&ve days. The FEV, theoretical values (%) are represented as a function of the dose (log,). b=FEV, at the 
beginning of the test. p=FEV, after inhalation of placebo (saline). 
TABLE 2. Cholinergic provacation lasts before and after TDI challenge 
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Patient 
PD 20 
(log 2) 
Before TDI After TDI 
% fall FEVI 
at PD 20 
% fall observed PD 20 % fall % fall FEVl A log 
FEVl after TDI (1% 2) FEVl at PD 20 PD20 
1 9 14.3 8.3 7 20 20 2* 
2 8 21.2 9.1 7 27.3 27.3 1 
3 8 20.8 - 4.2 5 20.8 20.8 3 
4 7 36.7 36.7 7 30.0 30 0 
5 7 34.9 7 6 23.2 23.2 1 
6 8 2.6 8 - 3.1 0 
7 5 23.2 23.2 5 20.7 20.7 0 
8 I 36.4 2.2 6 23.3 23.3 1 
9 5 24.4 7.2 2 22.5 225 3 
10 8 5.6 8 17.5 - 0 
11 I 20.2 16.9 6 23.5 23.5 1 
Mean 21.8 118f 20.5 23.5? 
SD 11.4 12.2 8.5 3.2 
*: for patient 1, since a fall in FEVl of less than 20% occurred at dose 8, a 20% fall in FEVl was extrapolated as dose 9. 
t: ~~0.02 between before and after TDl for @XI fall FEVl at PD 20 observed after TDI at cholinergic challenges (Wilcoxon 
paired rank test). 
non-specific cholinergic tests after a negative provocation 
test may provide an objective index in the diagnosis of 
occupational asthma. This would be important progress, 
in view of the difficulty in performing TDI bronchial 
provocation tests, their limited diagnostic use, and 
especially the large number of false-negative results in the 
diagnosis of occupational asthma (9). 
In conclusion, our study shows the occurrence of a slight 
but significant increase in BHR after patients with a clinical 
history of asthma are exposed to repeated low doses 
of isocyanate. This result may be important in view of 
the possibly high percentage of undetected cases of occu- 
pational asthma. These results, which require confirma- 
tion, may justify a proposal to measure non-specific BHR, 
even after a negative specific inhalation test to TDI, as 
an additional diagnostic element for TDI-induced 
occupational asthma. 
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